Trial Profile
A double-blind, randomized, placebo-controlled, study of the safety and activity of four escalating single doses of AVE0657 in patients suffering from Obstructive Sleep Apnea Hypopnea Syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Oct 2021
Price :
$35
*
At a glance
- Drugs AVE 0657 (Primary)
- Indications Sleep apnoea syndrome
- Focus Therapeutic Use
- 18 Aug 2011 New trial record